









Märkte
/
Aktien
/
nasdaq-crmd
/

CorMedix Inc

CRMD

7.690USD

+0.340+4.63%

Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert

602.50MMarktkapitalisierung

3.24KGV TTM



CorMedix Inc

7.690

+0.340+4.63%

Übersicht Finanzen Analyse Unternehmen

Übersicht

Finanzen

Analyse

Unternehmen

mehr Informationen über CorMedix Inc Unternehmen

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

CorMedix Inc Informationen



BörsenkürzelCRMD

Name des UnternehmensCorMedix Inc

IPO-datumMar 25, 2010

CEOTodisco (Joseph)

Anzahl der mitarbeiter64

WertpapierartOrdinary Share

GeschäftsjahresendeMar 25

Addresse300 Connell Drive

StadtBERKELEY HEIGHTS

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl07922

Telefon19085179500

Websitehttps://cormedix.com/

BörsenkürzelCRMD

IPO-datumMar 25, 2010

CEOTodisco (Joseph)

Führungskräfte von CorMedix Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

567.46K

+77156.00%

Mr. Steven W. Lefkowitz

Independent Director

133.10K

+45453.00%

Ms. Susan Blum

Chief Financial Officer

132.74K

+63053.00%

Ms. Janet M. Dillione

Independent Director

43.93K

+20453.00%

Mr. Gregory Scott (Greg) Duncan

Independent Director

43.79K

+30453.00%

Mr. Robert Stewart

Independent Director

41.45K

+30453.00%

Mr. Myron M. Kaplan, J.D.

Independent Chairman of the Board

Dr. Alan William Dunton, M.D.

Independent Director

Ms. Elizabeth (Liz) Massonhurlburt

Chief Operating Officer

Dr. Matthew T. (Matt) David, M.D.

Chief Business Officer

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

567.46K

+77156.00%

Mr. Steven W. Lefkowitz

Independent Director

133.10K

+45453.00%

Ms. Susan Blum

Chief Financial Officer

132.74K

+63053.00%

Ms. Janet M. Dillione

Independent Director

43.93K

+20453.00%

Mr. Gregory Scott (Greg) Duncan

Independent Director

43.79K

+30453.00%

Mr. Robert Stewart

Independent Director

41.45K

+30453.00%

Umsatzaufteilung

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach RegionUSD

Name

Umsatz

Anteil

United States

104.28M

0.00%

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, Jan 29

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.69%

Marshall Wace LLP

4.41%

Andere

71.37%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.69%

Marshall Wace LLP

4.41%

Andere

71.37%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

27.93%

Hedge Fund

16.86%

Investment Advisor/Hedge Fund

15.44%

Individual Investor

8.00%

Research Firm

2.04%

Pension Fund

1.11%

Bank and Trust

0.32%

Insurance Company

0.03%

Venture Capital

0.03%

Andere

28.23%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

338

43.86M

55.93%

+10.78K

2025Q3

340

43.85M

56.33%

+8.67M

2025Q2

304

34.76M

43.08%

+9.67M

2025Q1

267

24.95M

43.35%

-4.41M

2024Q4

241

23.99M

39.87%

+4.76M

2024Q3

216

19.17M

36.31%

+1.94M

2024Q2

207

17.23M

38.40%

-272.84K

2024Q1

207

17.37M

41.54%

-5.46M

2023Q4

207

18.82M

39.64%

+838.41K

2023Q3

199

17.96M

39.30%

-1.31M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

5.04M

6.4%

+248.22K

+5.18%

Sep 30, 2025

Deep Track Capital LP

4.96M

6.29%

+4.46M

+891.10%

Nov 21, 2025

Abdalkader (Shaibatalhamd Aymen)

4.65M

6.22%

+4.65M

Aug 08, 2025

The Vanguard Group, Inc.

3.96M

5.03%

-347.89K

-8.07%

Sep 30, 2025

Marshall Wace LLP

3.47M

4.41%

+893.52K

+34.63%

Sep 30, 2025

Deerfield Management Company, L.P.

3.32M

4.22%

+3.32M

Sep 30, 2025

State Street Investment Management (US)

1.84M

2.33%

+233.97K

+14.61%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.81M

2.3%

+213.45K

+13.37%

Sep 30, 2025

Citadel Advisors LLC

1.72M

2.18%

+2.87K

+0.17%

Sep 30, 2025

Alyeska Investment Group, L.P.

1.26M

1.6%

+512.98K

+68.40%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

State Street SPDR S&P Pharmaceuticals ETF

2.01%

Invesco Biotechnology & Genome ETF

1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.52%

VictoryShares Small Cap Free Cash Flow ETF

0.79%

First Trust Active Factor Small Cap ETF

0.3%

Janus Henderson Small Cap Growth Alpha ETF

0.25%

ALPS Barron's 400 ETF

0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.19%

Vanguard US Multifactor ETF

0.16%

iShares Micro-Cap ETF

0.15%

State Street SPDR S&P Pharmaceuticals ETF

Anteil2.01%

Invesco Biotechnology & Genome ETF

Anteil1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Anteil1.52%

VictoryShares Small Cap Free Cash Flow ETF

Anteil0.79%

First Trust Active Factor Small Cap ETF

Anteil0.3%

Janus Henderson Small Cap Growth Alpha ETF

Anteil0.25%

ALPS Barron's 400 ETF

Anteil0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

Anteil0.19%

Vanguard US Multifactor ETF

Anteil0.16%

iShares Micro-Cap ETF

Anteil0.15%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

KeyAI

